Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEOMICS: Proteomics to Identify Biomarkers of Response to Mepolizumab in EGPA
NCT07343661Phase 4Enrolling by invitation
- Sponsor
- Azienda Ospedaliero Universitaria di Cagliari
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA), eosinophilic asthma (EA), sponsored by Azienda Ospedaliero Universitaria di Cagliari. Started Oct 2025; status: enrolling by invitation.
02
Drugs
mepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT07343661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07343661.